Literature DB >> 10441585

Mapping of the mucolipidosis type IV gene to chromosome 19p and definition of founder haplotypes.

S A Slaugenhaupt1, J S Acierno, L A Helbling, C Bove, E Goldin, G Bach, R Schiffmann, J F Gusella.   

Abstract

Mucolipidosis type IV (MLIV) is a lysosomal storage disorder characterized by severe neurologic and ophthalmologic abnormalities. It is a rare autosomal recessive disease, and the majority of patients diagnosed, to date, are of Ashkenazi Jewish descent. We have mapped the MLIV gene to chromosome 19p13.2-13.3 by linkage analysis with 15 markers in 13 families. A maximum LOD score of 5.51 with no recombinants was observed with marker D19S873. Several markers in the linked interval also displayed significant linkage disequilibrium with the disorder. We constructed haplotypes in 26 Ashkenazi Jewish families and demonstrate the existence of two founder chromosomes in this population. The localization of MLIV to chromosome 19 will permit genetic prenatal diagnosis in affected families and will aid in the isolation of the disease gene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10441585      PMCID: PMC1377985          DOI: 10.1086/302549

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  14 in total

1.  Mucolipidosis type IV: abnormal transport of lipids to lysosomes.

Authors:  R Bargal; G Bach
Journal:  J Inherit Metab Dis       Date:  1997-09       Impact factor: 4.982

2.  Faster linkage analysis computations for pedigrees with loops or unused alleles.

Authors:  A A Schäffer
Journal:  Hum Hered       Date:  1996 Jul-Aug       Impact factor: 0.444

3.  Abnormal transport along the lysosomal pathway in mucolipidosis, type IV disease.

Authors:  C S Chen; G Bach; R E Pagano
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

4.  Congenital corneal clouding with abnormal systemic storage bodies: a new variant of mucolipidosis.

Authors:  E R Berman; N Livni; E Shapira; S Merin; I S Levij
Journal:  J Pediatr       Date:  1974-04       Impact factor: 4.406

5.  Use of cyclosporin A in establishing Epstein-Barr virus-transformed human lymphoblastoid cell lines.

Authors:  M A Anderson; J F Gusella
Journal:  In Vitro       Date:  1984-11

6.  Easy calculations of lod scores and genetic risks on small computers.

Authors:  G M Lathrop; J M Lalouel
Journal:  Am J Hum Genet       Date:  1984-03       Impact factor: 11.025

7.  Constitutive achlorhydria in mucolipidosis type IV.

Authors:  R Schiffmann; N K Dwyer; I A Lubensky; M Tsokos; V E Sutliff; J S Latimer; K P Frei; R O Brady; N W Barton; E J Blanchette-Mackie; E Goldin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

8.  Review article: mucolipidosis IV.

Authors:  B F Crandall; M Philippart; W J Brown; D A Bluestone
Journal:  Am J Med Genet       Date:  1982-07

9.  Construction of human linkage maps: likelihood calculations for multilocus linkage analysis.

Authors:  G M Lathrop; J M Lalouel; R L White
Journal:  Genet Epidemiol       Date:  1986       Impact factor: 2.135

10.  Mucolipidosis type IV: clinical spectrum and natural history.

Authors:  N Amir; J Zlotogora; G Bach
Journal:  Pediatrics       Date:  1987-06       Impact factor: 7.124

View more
  37 in total

1.  Carrier screening for mucolipidosis type IV in the American Ashkenazi Jewish population.

Authors:  Lisa Edelmann; Jianli Dong; Robert J Desnick; Ruth Kornreich
Journal:  Am J Hum Genet       Date:  2002-02-13       Impact factor: 11.025

2.  Geographic distribution of disease mutations in the Ashkenazi Jewish population supports genetic drift over selection.

Authors:  Neil Risch; Hua Tang; Howard Katzenstein; Josef Ekstein
Journal:  Am J Hum Genet       Date:  2003-02-24       Impact factor: 11.025

3.  A population-genetic test of founder effects and implications for Ashkenazi Jewish diseases.

Authors:  Montgomery Slatkin
Journal:  Am J Hum Genet       Date:  2004-06-18       Impact factor: 11.025

Review 4.  TRPMLs: in sickness and in health.

Authors:  Rosa Puertollano; Kirill Kiselyov
Journal:  Am J Physiol Renal Physiol       Date:  2009-01-21

5.  N-butyldeoxynojirimycin delays motor deficits, cerebellar microgliosis, and Purkinje cell loss in a mouse model of mucolipidosis type IV.

Authors:  Lauren C Boudewyn; Jakub Sikora; Ladislav Kuchar; Jana Ledvinova; Yulia Grishchuk; Shirley L Wang; Kostantin Dobrenis; Steven U Walkley
Journal:  Neurobiol Dis       Date:  2017-06-10       Impact factor: 5.996

Review 6.  Role of TRP channels in the regulation of the endosomal pathway.

Authors:  Ken Abe; Rosa Puertollano
Journal:  Physiology (Bethesda)       Date:  2011-02

7.  2016 William Allan Award: Human Disease Research: Genetic Cycling and Re-cycling.

Authors:  James F Gusella
Journal:  Am J Hum Genet       Date:  2017-03-02       Impact factor: 11.025

8.  The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris.

Authors:  José A Martina; Heba I Diab; Li Lishu; Lim Jeong-A; Simona Patange; Nina Raben; Rosa Puertollano
Journal:  Sci Signal       Date:  2014-01-21       Impact factor: 8.192

9.  Novel Role of TRPML2 in the Regulation of the Innate Immune Response.

Authors:  Lu Sun; Yinan Hua; Silvia Vergarajauregui; Heba I Diab; Rosa Puertollano
Journal:  J Immunol       Date:  2015-10-02       Impact factor: 5.422

Review 10.  Mucolipin 1: endocytosis and cation channel--a review.

Authors:  Gideon Bach
Journal:  Pflugers Arch       Date:  2004-11-27       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.